<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-4085</journal-id>
<journal-title><![CDATA[Revista mexicana de urología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. urol.]]></abbrev-journal-title>
<issn>2007-4085</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-40852017000300199</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Expresión de microARNs circulantes como opción para la detección de cáncer de próstata]]></article-title>
<article-title xml:lang="en"><![CDATA[Circulating miRNA expression as a clinical option for the detection of prostate cancer]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez-Báez]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Comoto-Santacruz]]></surname>
<given-names><![CDATA[DA.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Huerta-Núñez]]></surname>
<given-names><![CDATA[LFE.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Campos-Saucedo]]></surname>
<given-names><![CDATA[JG.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Estrada-Carrasco]]></surname>
<given-names><![CDATA[CE.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad del Ejército y Fuerza Aérea Escuela Militar de Graduados de Sanidad Laboratorio de Biología Molecular]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Central Militar Servicio de Urología ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<volume>77</volume>
<numero>3</numero>
<fpage>199</fpage>
<lpage>206</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-40852017000300199&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-40852017000300199&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-40852017000300199&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  ANTECEDENTES:  los microARNs (miARNs) son moléculas alteradas del tejido tumoral prostático, incluso en casos de resistencia farmacológica. Los miARNs son importantes reguladores de la expresión génica que participan en varios procesos patológicos. Estas moléculas, detectables en muestras sanguíneas, funcionan como biomarcadores de diagnóstico, pronóstico y respuesta al tratamiento del cáncer de próstata.  OBJETIVO:  determinar el perfil de expresión de los miARNs mediante técnicas moleculares en pacientes con cáncer de próstata.  MATERIALES Y MÉTODOS:  estudio de casos y controles, efectuado en muestras de sangre de pacientes con diagnóstico de cáncer de próstata. Extracción del ARN total del suero, síntesis de cADN, qRTPCR y análisis de la expresión de los miARNs.  RESULTADOS:  se obtuvieron 20 muestras sanguíneas para análisis molecular de miARNs. El análisis de la expresión de 62 miARNs reveló que 9 tuvieron expresión alterada, de éstos 5 están reportados en la bibliografía como marcadores de cáncer de próstata resistente a la castración.  CONCLUSIÓN: la identificación de los miARNs mediante métodos no invasivos es una opción para detectar y diagnosticar cáncer de próstata y estimar el pronóstico de los pacientes con riesgo de resistencia al tratamiento farmacológico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  BACKGROUND:  MicroRNA molecules are altered in cancerous prostate tissue. This is also true in the drug-resistant cases. MicroRNAs are important regulators of gene expression and they are involved in various pathologic processes. These molecules have been reported as diagnostic, prognostic, and treatment response biomarkers in prostate cancer.  OBJECTIVE:  To determine the microRNA expression profile through molecular biology techniques in patients with prostate cancer.  MATERIALS AND METHODS:  A case-control study was conducted that analyzed blood samples from patients diagnosed with prostate cancer for serum total RNA extraction, cDNA synthesis, qRT-PCR, and microRNA expression analysis.  RESULTS:  Twenty blood samples were collected for molecular miRNA study. Sixty-two microRNAs were analyzed and 9 of them were revealed to have altered expression. Five of those 9 are reported in the international literature as castration-resistant prostate cancer markers.  DISCUSSION AND CONCLUSIONS: There is clear evidence of the relation between miRNAs and their function in pathologic processes. For example, the miR-375 gene is related to proliferation and epithelial-mesenchymal transition; miR-143 is related to migration and invasion; and miR-31 is related to the androgen receptor. This could improve the biomarkers already established in prostate cancer. The identification of miRNAs through noninvasive methods is a useful tool for the detection and diagnosis of prostate cancer, as well as for the prognosis of patients at risk for developing drug resistance in relation to their treatment.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[miARN]]></kwd>
<kwd lng="es"><![CDATA[resistencia farmacológica]]></kwd>
<kwd lng="es"><![CDATA[expresión génica]]></kwd>
<kwd lng="en"><![CDATA[MiRNA]]></kwd>
<kwd lng="en"><![CDATA[Drug resistance]]></kwd>
<kwd lng="en"><![CDATA[Gene expresión]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiménez-Ríos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Solares-Sánchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Cervera]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Aguilar-Ponce]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-Cedillo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hinojosa-Gómez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncoguía: Cáncer de próstata]]></article-title>
<source><![CDATA[Cancerología]]></source>
<year>2011</year>
<volume>6</volume>
<page-range>13-8</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gutiérrez]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera-Dommarco]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shamah-Levy]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Encuesta Nacional de Salud y Nutrición 2012. Resultados nacionales, Cuernavaca, México]]></source>
<year>2012</year>
<page-range>1-196</page-range><publisher-name><![CDATA[Instituto Nacional de Salud Pública]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Otero]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[BG]]></given-names>
</name>
<name>
<surname><![CDATA[Juanatey]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Touijer]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate cancer biomarkers: An update. Urologic oncology: Seminars and original investigations]]></article-title>
<source><![CDATA[Urol Oncol]]></source>
<year>2014</year>
<page-range>252-60</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lilja]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Testing new PSA subforms to enhance the accuracy of predicting cancer risk and disease outcome in prostate cancer]]></article-title>
<source><![CDATA[Clin Chem]]></source>
<year>2008</year>
<volume>54</volume>
<page-range>1248-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lilja]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ulmert]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Vickers]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate-specific antigen and prostate cancer: prediction, detection and monitoring]]></article-title>
<source><![CDATA[Nature Rev Cancer]]></source>
<year>2008</year>
<volume>8</volume>
<page-range>268-78</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cary]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Cooperberg]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biomarkers in prostate cancer surveillance and screening: past, present, and future]]></article-title>
<source><![CDATA[Ther Adv Urol]]></source>
<year>2013</year>
<volume>5</volume>
<page-range>318-29</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PSA and beyond: alternative prostate cancer biomarkers]]></article-title>
<source><![CDATA[Cell Oncol]]></source>
<year>2016</year>
<volume>39</volume>
<page-range>97-106</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sawyers]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The cancer biomarker problem]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2008</year>
<volume>452</volume>
<page-range>548-52</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prensner]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Rubin]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Wei]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Chinnaiyan]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Beyond PSA: the next generation of prostate cancer biomarkers]]></article-title>
<source><![CDATA[Sci Translat Med]]></source>
<year>2012</year>
<volume>4</volume>
<page-range>127rv3</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ilyin]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Belkowski]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Plata-Salamán]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biomarker discovery and validation: technologies and integrative approaches]]></article-title>
<source><![CDATA[Trends Biotech]]></source>
<year>2004</year>
<volume>22</volume>
<page-range>411-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graves]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Zeng]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biogenesis of mammalian microRNAs: a global view]]></article-title>
<source><![CDATA[Genomics Proteomics Bioinformatics]]></source>
<year>2012</year>
<volume>10</volume>
<page-range>239-45</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Ba]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases]]></article-title>
<source><![CDATA[Cell Res]]></source>
<year>2008</year>
<volume>18</volume>
<page-range>997-1006</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jackson]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
<name>
<surname><![CDATA[Grabowska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ratan]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers]]></article-title>
<source><![CDATA[BMC Cancer]]></source>
<year>2014</year>
<volume>14</volume>
<page-range>1</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mahato]]></surname>
<given-names><![CDATA[RI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MicroRNAs and drug resistance in prostate cancers]]></article-title>
<source><![CDATA[Mol Pharm]]></source>
<year>2014</year>
<volume>11</volume>
<page-range>2539-52</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Massard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Fizazi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeting continued androgen receptor signaling in prostate cancer]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2011</year>
<volume>17</volume>
<page-range>3876-83</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[W-J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MicroRNAs in prostate cancer]]></article-title>
<source><![CDATA[Prostate international]]></source>
<year>2013</year>
<volume>1</volume>
<page-range>3-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ozen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Creighton]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ozdemir]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ittmann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Widespread deregulation of microRNA expression in human prostate cancer]]></article-title>
<source><![CDATA[Oncogene]]></source>
<year>2008</year>
<volume>27</volume>
<page-range>1788-93</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Porkka]]></surname>
<given-names><![CDATA[KP]]></given-names>
</name>
<name>
<surname><![CDATA[Pfeiffer]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Waltering]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Vessella]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Tammela]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[Visakorpi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MicroRNA expression profiling in prostate cancer]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2007</year>
<volume>67</volume>
<page-range>6130-5</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gordanpour]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Nam]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sugar]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Seth]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MicroRNAs in prostate cancer: from biomarkers to molecularly-based therapeutics]]></article-title>
<source><![CDATA[Prostate Cancer Prostatic Dis]]></source>
<year>2012</year>
<volume>15</volume>
<page-range>314-9</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hurst]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Edmonds]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Welch]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metastamir: the field of metastasis-regulatory microRNA is spreading]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2009</year>
<volume>69</volume>
<page-range>7495-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Majid]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dahiya]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diet, microRNAs and prostate cancer]]></article-title>
<source><![CDATA[Pharm Res]]></source>
<year>2010</year>
<volume>27</volume>
<page-range>1014-26</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Szczyrba]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Löprich]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Wach]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The microRNA profile of prostate carcinoma obtained by deep sequencing]]></article-title>
<source><![CDATA[Mol Cancer Res]]></source>
<year>2010</year>
<volume>8</volume>
<page-range>529-38</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hessvik]]></surname>
<given-names><![CDATA[NP]]></given-names>
</name>
<name>
<surname><![CDATA[Sandvig]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Llorente]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exosomal miRNAs as biomarkers for prostate cancer]]></article-title>
<source><![CDATA[Front Genet]]></source>
<year>2014</year>
<volume>21</volume>
<page-range>36</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ambs]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Prueitt]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Yi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2008</year>
<volume>68</volume>
<page-range>6162-70</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brase]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Johannes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schlomm]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Circulating miRNAs are correlated with tumor progression in prostate cancer]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2011</year>
<volume>128</volume>
<page-range>608-16</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Selth]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Townley]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gillis]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2012</year>
<volume>131</volume>
<page-range>652-61</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lodes]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Caraballo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Suciu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Munro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Detection of cancer with serum miRNAs on an oligonucleotide microarray]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2009</year>
<volume>4</volume>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[LV]]></given-names>
</name>
<name>
<surname><![CDATA[Veliceasa]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Vinokour]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Volpert]]></surname>
<given-names><![CDATA[OV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[200b inhibits prostate cancer EMT, growth and metastasis]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2013</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Costa-Pinheiro]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Montezuma]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Henrique]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jerónimo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic and prognostic epigenetic biomarkers in cancer]]></article-title>
<source><![CDATA[Epigenomics]]></source>
<year>2015</year>
<volume>7</volume>
<page-range>1003-15</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bertoli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cava]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Castiglioni]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MicroRNAs as biomarkers for diagnosis, prognosis and theranostics in prostate cancer]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2016</year>
<volume>17</volume>
<page-range>421</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jalava]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Urbanucci]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Latonen]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer]]></article-title>
<source><![CDATA[Oncogene]]></source>
<year>2012</year>
<volume>31</volume>
<page-range>4460-71</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Fang]]></surname>
<given-names><![CDATA[YX]]></given-names>
</name>
<name>
<surname><![CDATA[Xue]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[JZ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Four microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals in vitro]]></article-title>
<source><![CDATA[PloS one]]></source>
<year>2013</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haldrup]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kosaka]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ochiya]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Profiling of circulating microRNAs for prostate cancer biomarker discovery]]></article-title>
<source><![CDATA[Drug Deliv Transl Res]]></source>
<year>2014</year>
<volume>4</volume>
<page-range>19-30</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[P-C]]></given-names>
</name>
<name>
<surname><![CDATA[Chiu]]></surname>
<given-names><![CDATA[Y-L]]></given-names>
</name>
<name>
<surname><![CDATA[Banerjee]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2013</year>
<volume>73</volume>
<page-range>1232-44</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peng]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of miRs-143 and-145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT]]></article-title>
<source><![CDATA[PloS One]]></source>
<year>2011</year>
<volume>6</volume>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Deng]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Down&#8208;regulation of miR&#8208;200b&#8208;3p by low p73 contributes to the androgen&#8208;independence of prostate cancer cells]]></article-title>
<source><![CDATA[Prostate]]></source>
<year>2013</year>
<volume>73</volume>
<page-range>1048-56</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kojima]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Fujita]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nozawa]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Deguchi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[MiR&#8208;34a attenuates paclitaxel&#8208;resistance of hormone&#8208;refractory prostate cancer PC3 cells through direct and indirect mechanisms]]></article-title>
<source><![CDATA[Prostate]]></source>
<year>2010</year>
<volume>70</volume>
<page-range>1501-12</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
